StemCellPatents.com Applauds Blasticon for Issuance of Breakthrough Stem Cell Patent.TORONTO -- StemCellPatents.com congratulates the German biotech company Blasticon Biotechnologische Forschung GmbH for issuance of a US patent, which in the opinion of StemCellPatents.com, may lead to a revolution in stem cell therapeutics. "We at StemCellPatents.com try to disseminate critical findings in the area of stem cell research. By identifying key discoveries and devising ways to improve upon them, we believe the rate of clinical translation of stem cell sciences can be greatly accelerated," stated Dr. Zhoahui Zhong, Chairman of StemCellPatents.com. It appears that the issued US patent # 7,138,275 discloses methods and examples of taking peripheral blood monocytes monocytes, n.pl the largest of the white blood cells. They have one nucleus and a large amount of grayish-blue cytoplasm. Develop into macrophages and both consume foreign material and alert T cells to its presence. , de-differentiating them using commonly available cytokines Cytokines Chemicals made by the cells that act on other cells to stimulate or inhibit their function. Cytokines that stimulate growth are called "growth factors. such as M-CSF and IL-3, and redifferentiating them into various tissues such as islets, hepatocytes, or neurons. The patent provides not only morphological, but also phenotypic and functional evidence that cells derived from the "reprogrammed monocyte monocyte /mono·cyte/ (mon´o-sit) a mononuclear, phagocytic leukocyte, 13µ to 25µ in diameter, with an ovoid or kidney-shaped nucleus, and azurophilic cytoplasmic granules. stem cell" actually are the tissues that they are claimed to be. Since monocytes can be derived in large quantities from peripheral blood, this patent may be used to generate large quantities of patient-specific stem cells so as to avoid the need for allogeneic allogeneic /al·lo·ge·ne·ic/ (-je-ne´ik) 1. having cell types that are antigenically distinct. 2. in transplantation biology, denoting individuals (or tissues) that are of the same species but antigenically donors or immune suppression. "Readers of StemCellPatents.com will quickly see new ways in which the scope of this patent can be broadened by synergizing it with existing patents described on our website. For example, one could use the retrodifferentiation technology described in US patent application #20040199935 which is owned by Advanced Cell Technology, to augment the potency and yield of stem cells generated according to the current patent. Alternatively, one could generate autologous autologous /au·tol·o·gous/ (aw-tol´ah-gus) related to self; belonging to the same organism. au·tol·o·gous adj. 1. neural cells from monocytes as thought in the # 7,138,275 patent, and administer them for accelerating hematopoietic hematopoietic /he·ma·to·poi·et·ic/ (-poi-et´ik) 1. pertaining to hematopoiesis. 2. an agent that promotes hematopoiesis. hematopoietic 1. pertaining to or affecting the formation of blood cells. engraftment engraftment /en·graft·ment/ (en-graft´ment) incorporation of grafted tissue into the body of the host. Engraftment The process of transplanted stem cells reproducing new cells. according to US Patent # 6,897,060 held by Neurosphere Holdings," concluded Dr. Zhong. About StemCellPatents.com StemCellPatents.com is an informal organization of concerned scientists, lawyers and intellectuals that assembled the only comprehensive index of all issued US stem cell patents: accessible freely as a Beta Version at www.stemcellpatents.com. StemCellPatents.com is not affiliated in any manner with Blasticon Biotechnologische Forschung GmbH and the views presented herein are only those of StemCellPatents.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion